LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

DaVita Inc

Suletud

SektorTervishoid

145.18 1.28

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

142.27

Max

145.18

Põhinäitajad

By Trading Economics

Sissetulek

135M

349M

Müük

35M

3.3B

P/E

Sektori keskmine

13.473

56.602

Aktsiakasum

2

Kasumimarginaal

10.6

Töötajad

76,000

EBITDA

11M

729M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+11.19% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-3.4B

11B

Eelmine avamishind

143.9

Eelmine sulgemishind

145.18

Uudiste sentiment

By Acuity

55%

45%

319 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

DaVita Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. veebr 2025, 19:50 UTC

Suurimad hinnamuutused turgudel

DaVita Stock Declines After Outlook Miss, Berkshire Hathaway Sales

21. märts 2025, 08:19 UTC

Market Talk

Fresenius Medical Care's Revenue Estimates Lowered by Jefferies on U.S. Volume Concerns -- Market Talk

15. juuli 2024, 08:17 UTC

Market Talk

Fresenius Medical Care, DaVita Brace for Competition, Shift to Home Dialysis -- Market Talk

Võrdlus sarnastega

Hinnamuutus

DaVita Inc Prognoos

Hinnasiht

By TipRanks

11.19% tõus

12 kuu keskmine prognoos

Keskmine 159.67 USD  11.19%

Kõrge 169 USD

Madal 145 USD

Põhineb 4 Wall Streeti analüütiku instrumendi DaVita Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

0

Osta

3

Hoia

1

Müü

Tehniline skoor

By Trading Central

142.36 / 144.275Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

319 / 382 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest DaVita Inc

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.